By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts. - 2Kendall Jenner addresses long-standing rumor about her sexuality
- 3Hamas propaganda expert explains Israel's internal conflicts influenced Hamas's Oct. 7 assault
- 4Top notch Remote Earphones for Audiophiles
- 5Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel
- FDA proposes use of sunscreen ingredient popular in other countries
- A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- See the 'amazing' photos of Earth taken on historic Artemis II moon mission
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- Israeli lawmakers pass bill reviving death penalty for terrorists
- Director of Swiss hospital describes the rush to treat the injured from Alpine resort bar fire
- ‘Grit’ and relentless perseverance can take a toll on brain health − particularly for people facing social stresses like racism
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
